Hematologic Malignancies Clinical Trial
Official title:
Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant
The objective of this study is to compare the safety and efficacy of ABLC versus oral
Posaconazole in the prevention of invasive fungal infections in high risk patients with
hematologic malignancies or hematopoietic stem cell transplant.
Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal
infections associated with ABLC or Posaconazole prophylaxis.
Secondary objective will be to compare the cost effectiveness of these two prophylactic
regimens.
The Study Drugs:
ABLC is an antifungal drug that is commonly used to treat and/or prevent a variety of
serious invasive fungal infections (IFIs). In this study, ABLC will be used for IFI
prevention.
Posaconazole is a newer antifungal drug that is commonly used to prevent serious IFIs.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the toss of a coin) to receive either posaconazole or ABLC. You will have an equal
chance (50/50) of being assigned to either group. You and your study doctor will know which
group you are in.
Study Drug Administration:
If you are assigned to the Posaconazole Group, you will take posaconazole 3 times a day by
mouth for up to 6 weeks (Days 1-42). The study doctor will advise you about taking it with
fatty meals and/or nutritional supplements.
If you are assigned to the ABLC Group, you will receive ABLC once a week by vein over 4-6
hours, for up to 6 weeks (from Day 1 through Day 42). If the creatinine level increases, the
dose will be divided into 2 doses per week. The drug may be given in the hospital (if you
are admitted to the hospital before or during the study) or at an outpatient treatment
center.
Study Visits:
Once a week from Day 1 to Day 42, you will have the following procedures performed:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will be asked about any medications and treatments you may be receiving.
- You will be asked about any IFI symptoms that may have developed. You will also be
asked about any side effects that may have occurred since your last visit. (You should
contact the study doctor and/or study staff right away, if at any time you feel you
have had a side effect.)
You may have certain routine diagnostic tests performed at any time in the study, if
necessary to confirm you do not have an IFI. These tests may include blood collection (about
1 tablespoon), scans, skin tissue biopsy, and/or bronchoscopy.
Length of Study:
You will receive study treatment for up to 6 weeks (42 days). If you develop an IFI or any
intolerable side effects, you will be taken off study early. You may also be taken off study
if your neutrophil (a type of white blood cell) counts recover.
End-of-Treatment Visit:
Your End-of-Treatment visit will be on the last day you received the study drug (at most, 42
days after you started). The following procedures will be performed.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam, including measurement of vital signs.
- If the study doctor and/or your primary doctor thinks you may have an IFI, routine
diagnostic tests may be performed.
Follow-up Visit:
Your follow up visit will be completed 7 - 14 days after your end-of-treatment visit. The
following procedures will be performed:
- You will be checked for any signs of IFI.
- If your doctor suspects you have an IFI, a scan (such as an x-ray or CT scan) and/or
bronchoscopy may be performed.
- You will be asked about any medications and treatments you may be receiving, and any
side effects you may have had.
- Your vital signs will be checked, and a physical exam may be performed.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- An ECG may be performed.
This is an investigational study. ABLC and posaconazole are FDA approved and commercially
available for the treatment and prevention of IFIs. Posaconazole is FDA approved for the way
it is being used in this study. The study dose and study schedule for ABLC, however, is
considered experimental. Currently, this dose and schedule for ABLC is being used in
research only.
Up to 100 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 |